IGKC and non-small cell lung carcinoma: Schmidt et al. reported that IGKC is a novel diagnostic marker for risk stratification in NSCLC and supported concepts to exploit the humoral immune response for anticancer therapy, which could be validated by transcriptomics and immunostaining at the protein level (17).